Is cefixime 200 mg twice daily for five days combined with azithromycin 500 mg once daily for five days an appropriate treatment regimen for persistent typhoid infection?

Treatment Recommendation for Persistent Typhoid Fever

The combination of cefixime 200 mg twice daily plus azithromycin 500 mg once daily for 5 days is NOT supported by current evidence and should NOT be used for persistent typhoid infection. Instead, use azithromycin 500 mg once daily alone for 7 days, or switch to ceftriaxone or meropenem if azithromycin fails 1.

Why This Combination Doesn't Work

The most recent and highest-quality evidence directly addresses this exact question. The ACT-South Asia trial (2026) was a large, double-blind, randomized controlled trial involving 1,831 patients across Nepal, Bangladesh, and Pakistan that specifically tested azithromycin plus cefixime versus azithromycin alone 1. The results showed absolutely no benefit to adding cefixime:

• Treatment failure occurred in 5.1% of patients in both groups (identical rates)
• Even in culture-confirmed typhoid cases, the combination showed no significant advantage (11.2% vs 16.0% failure, p=0.20)
• Adverse events were similar between groups (16% in both)

This trial definitively answers your question: adding cefixime to azithromycin provides no clinical benefit.

What You Should Do Instead

For Uncomplicated Typhoid Fever:

First-line treatment: Azithromycin 500 mg once daily for 7 days (not 5 days) 2, 1

• WHO guidelines support azithromycin as the preferred agent 2
• Evidence shows azithromycin has lower clinical failure rates (OR 0.48) and shorter hospital stays compared to fluoroquinolones 2
• Lower relapse rates (OR 0.09) compared to ceftriaxone 2

If Azithromycin Fails or Resistance Suspected:

Second-line options:

• Ceftriaxone (for quinolone-resistant strains) 2
• Cefixime alone (for multidrug-resistant but not ESBL-producing strains) 2

For Extensively Drug-Resistant (XDR) Typhoid:

Use meropenem with or without azithromycin 3, 4

Critical Pitfalls to Avoid

1. Duration matters: The standard azithromycin regimen is 7 days, not 5 days. The FDA-approved dosing for azithromycin shows that 5-day regimens are used for respiratory infections, not typhoid 5. Shortening to 5 days may increase treatment failure.

2. Don't assume combination is better: The hypothesis that combining intracellular (azithromycin) and extracellular (cefixime) activity would improve outcomes was logical but proven wrong by rigorous trial data 1.

3. Persistent fever doesn't always mean treatment failure: One case report showed a patient remaining febrile for 11 days despite appropriate meropenem-azithromycin therapy for ESBL-producing typhoid, yet ultimately recovered 4. Don't prematurely switch antibiotics if the patient is otherwise improving clinically.

4. Know your local resistance patterns: Treatment choice must be guided by local antimicrobial susceptibility data 3. In areas with high fluoroquinolone resistance, azithromycin or ceftriaxone should be first-line 2.

Antimicrobial Stewardship Implications

The ACT-South Asia trial has major implications for antibiotic stewardship 1. Using unnecessary combination therapy:

• Increases antibiotic exposure without clinical benefit
• Potentially accelerates resistance development
• Increases cost and pill burden
• Raises adverse event risk

The trial authors explicitly state their findings "support the WHO recommendation of oral azithromycin alone" and provide "no evidence to support addition of cefixime" 1.

Bottom Line Algorithm

1. Suspected uncomplicated typhoid: Start azithromycin 500 mg once daily × 7 days
2. No improvement by day 7 OR known resistance: Switch to ceftriaxone or consider meropenem
3. ESBL-producing or XDR typhoid: Use meropenem ± azithromycin
4. Never use: Azithromycin + cefixime combination (no proven benefit)